. Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1. Am J Physiol Gastrointest Liver Physiol 281: G697-G704, 2001.-The nature of protein breakdown products and peptidomimetic drugs such as ␤-lactams is crucial for their transmembrane transport across apical enterocyte membranes, which is accomplished by the pH-dependent high-capacity oligopeptide transporter PEPT1. To visualize oligopeptide transporter-mediated uptake of oligopeptides, an ex vivo assay using the fluorophore-conjugated dipeptide derivative D-Ala-Lys-N⑀-7-amino-4-methylcoumarin-3-acetic acid (D-Ala-Lys-AMCA) was established in the murine small intestine and compared with immunohistochemistry for PEPT1 in murine and human small intestine. D-Ala-Lys-AMCA was accumulated by enterocytes throughout all segments of the murine small intestine, with decreasing intensity from the top to the base of the villi. Goblet cells did not show specific uptake. Inhibition studies revealed competitive inhibition by the ␤-lactam cefadroxil, the angiotensin-converting enzyme inhibitor captopril, and the dipeptide glycylglutamine. Controls were performed using either the inhibitor diethylpyrocarbonate or an incubation temperature of 4°C to exclude unspecific uptake. Immunohistochemistry for PEPT1 localized immunoreactivity to the enterocytes, with the highest intensity at the apical membrane. This is the first study that visualizes dipeptide transport across the mammalian intestine and indicates that uptake assays using D-AlaLys-AMCA might be useful for characterizing PEPT1-specific substrates or inhibitors.
peptidomimetics are taken up into the epithelium by the peptide transport system (8) . In this respect, the high oral availability of peptide-based drugs such as amino ␤-lactam antibiotics (6, 21, 34, 50) and angiotensin-converting enzyme (ACE) inhibitors (42, 48) results from their active transport mediated by the peptide transport system. In addition, antiviral (17, 19) and antineoplastic (22) agents as well as the precursor of porphyrine synthesis, ␦-aminolevulinic acid (11) (␦-ALA), have been identified as peptide transporter substrates. Uptake of these chemically distinct endogenous and exogenous compounds is accomplished by the pH-dependent H ϩ /peptide cotransporter PEPT1. The cDNAs encoding two mammalian proton-coupled peptide transporters have been cloned from rat (29, 37, 38) , rabbit (4, 5, 15) , and human tissues (24, 26) . Whereas PEPT1 protein and/or mRNA has been found in enterocytes from rat, rabbit, and human small intestine (16, 30, 31, 49) , and to a smaller extent in renal tubular cells (39, 40) , PEPT2 is expressed in the kidney (39, 40) , central nervous system (3, 10, 14) , and in a variety of peripheral tissues, including the lung (4, 18) . Both transporter isoforms possess 12 membrane-spanning domains, share an identity of ϳ47% at the protein level, and catalyze the electrogenic uphill transport of peptides by coupling it to the downhill movement of protons along an inwardly directed electrochemical proton gradient (9) .
Although there is a large body of information on function and kinetics of PEPT1-mediated transport in cell culture models and heterologous expression systems, techniques that visualize the transport of PEPT1-carried substrates in the intact intestine do not exist so far. Here we describe a new assay system employing a reporter molecule for rapid detection and visualization of peptide transport in intact tissue in combination with histochemical localization of PEPT1 immunoreactivity in the murine and human intestine.
METHODS
Adult BALB/c mice housed under standard laboratory conditions and fed ad libitum were used in the experiments. For uptake studies, 8 animals were used; 15 animals were used for immunohistochemistry studies. Ten specimens of human small intestine were obtained from remnants in excess of those required for pathological examination. The tissues were obtained after informed consent from patients. All specimens were examined histologically and did not display pathological features. All protocols were performed according to the Declaration of Helsinki and approved by the local ethics committee.
Ex vivo uptake studies. Animals of both sexes were killed by injection of pentobarbital sodium (40 mg/kg body wt ip). After laparotomy, the intestinal loops were mobilized and clipped proximal to the gastroduodenal junction and distal to the sigmoid. Then the loops were separated by morphological means to segments of 20-30 mm resembling duodenum, jejunum, ileum, and colon and isolated from each other by clipping the segments. The deceased animals were transferred to an incubation chamber (37°C), and a cannula was introduced into each segment.
Ex vivo uptake experiments were carried out by instillation of MEM (MEM 21011, GIBCO, Paisley, UK; gassed with 95% O2-5% CO2 at 37°C). MEM solution contained 25 M of the fluorophore-conjugated dipeptide D-Ala-L-Lys-N⑀-7-amino-4-methylcoumarin-3-acetic acid (D-Ala-Lys-AMCA) identified as a specific peptide transport substrate ( Fig. 1) (10, 32) . For inhibition studies, 1 mM unlabeled cefadroxil, glycyl-Lglutamine (Gly-L-Gln), or captopril (Sigma, Deisenhofen, Germany) was added to the 25 M D-Ala-Lys-AMCA-MEM solution ( Fig. 1) . Control experiments were performed by incubation in the presence of the transport inhibitor diethylpyrocarbonate (Sigma) (23, 44) , by incubation carried out at 4°C, and by omission of the fluorophore-labeled dipeptide.
Uptake studies were terminated by washing the segments through perfusion with ice-cold unlabeled MEM after 2, 4, 10, or 20 min. Tissues were removed, and fixation was carried out using 4% paraformaldehyde (PFA; T. J. Baker, Deventer, The Netherlands) in PBS at pH 7.4 for 5 min. The tissues were then immersed in 8% sucrose-PBS solution for cryoprotection and shock-frozen in liquid nitrogen-cooled isopentane. After cryostat cutting to 10-m sections, the slides were examined by epifluorescence microscopy.
Tissue preparation for immunohistochemistry. Human and murine tissues were fixed with 4% PFA in PBS at pH 7.4 for 2 h and processed for cryoprotection and freezing as described for the uptake studies. Animals were killed with pentobarbital sodium (40 mg/kg body wt ip) and perfused retrogradely through the abdominal aorta with 4% PFA in PBS at pH 7.4 for 5 min. Cryoprotection and freezing were carried out as described for the uptake studies.
Immunohistochemistry. Immunohistochemistry was performed as described previously (25) . Briefly, 10-m cryostat sections were mounted onto gelatin-chromalum-coated slides, air-dried for 30 min, and washed in PBS. Preincubation with 2% low-fat milk powder in Tris-buffered saline containing 1% Tween 20, pH 7.4, for 1 h at room temperature was followed by washes in PBS and incubation with a polyclonal anti-rabbit-PEPT1 serum raised against the COOH-terminal 15 amino acids of PEPT1 (sequence: H 2N-FRHRSKAYPKREHWC-COOH), diluted 1:1,000 in the preincubation solution overnight. For detection of the primary antibody, anti-rabbit indocarbocyanin antiserum (1:1,000, Dianova) was used. Control incubations without the primary antibody or preabsorption of the primary antibody with the corresponding antigenic peptide (concentration, 20 g protein/ml diluted antiserum) in parallel sections were carried out to specify the reaction. Slides were mounted in carbonate-buffered glycerol (pH 8.6) and viewed using epifluorescence microscopy and confocal laser scanning microscopy (LSM 10, Zeiss, Jena, Gemany).
RESULTS
Fluorophore-conjugated dipeptide uptake ex vivo. Localization of peptide transport activity in the murine intestine was performed by the novel fluorescent reporter molecule D-Ala-Lys-AMCA. Significant transmembrane transport of the reporter was detected by the accumulation of fluorescence in all murine small intestinal segments. Absorptive enterocytes displayed a strong uptake activity (Fig. 2) , and high-magnification microscopy allowed us to determine the histological pattern of the uptake activity in the various sections of the jejunum. The fluorescence signal was restricted to the cytoplasm of absorptive epithelial cells (Fig. 2b) . There was no visible accumulation of the reporter molecule in the nuclei (Fig. 2c) . The intensity was maximal in cells at the tip of the villi and decreased toward the crypt compartment. Goblet cells and vascular structures within the villi did not show any staining (Fig. 3a) . Cells of the lamina propria and muscularis also did not reveal any evidence for specific transport activity apart from a nonspecific background fluorescence. Maximal fluorescence accumulation was achieved after 10 min of incubation. For a more detailed analysis of the longitudinal distribution of transport activity along the gut samples of duodenum, we analyzed the jejunum, ileum, and colon (Fig. 3) . Absorptive enterocytes of all small intestine segments showed uptake of D-Ala-Lys-AMCA, whereas there was a complete lack of fluorescence in colonic samples (Fig. 3) .
For inhibition studies, murine gut segments were incubated with D-Ala-Lys-AMCA in the absence or presence of 1 mM unlabeled cefadroxil (Fig. 4b) , Gly-LGln (Fig. 4c), or captopril (Fig. 4d) . A very strong reduction in fluorescence intensity of the reporter was achieved by all three competitors (Fig. 4, b-d ) compared with control uptake (Fig. 4a) . No staining was obtained when incubations were performed with D-AlaLys-AMCA in the presence of the histidine-modifying agent diethylpyrocarbonate (Fig. 4e) or at an incubation temperature of 4°C (Fig. 4f) . Incubations in the absence of the reporter did not yield specific fluorescence accumulation apart from some nonspecific background fluorescence.
Immunohistochemistry. Histochemistry performed with a polyclonal antibody raised against PEPT1 detected specific fluorescence in the lamina mucosa but not in the lamina muscularis, tela submucosa, and serosa in human samples of ileum (Fig. 5a ). Along the murine intestine, duodenal, jejunal, and ileal segments showed PEPT1 immunoreactivity (Fig. 5) . There was no detectable PEPT1 signal present in sections of the human and murine colon. PEPT1 immunoreactivity was confined to absorptive enterocytes of the villi. The fluorescence signal was intense and of a nongranular type with labeling of the cytoplasm and was especially strong at the luminal brush-border membrane (Fig. 5) . Confocal laser scanning microscopy revealed a prominent signal at the luminal membrane (Fig. 5g) . Specific intracellular organelles such as nuclei, lysosomes, and Golgi apparatus were not stained. Epithelial mucussecreting goblet cells, connective tissue, and vascular structures also did not show specific PEPT1 immunoreactivity. Some cells of the lamina propria were labeled, but this signal was also present when the primary antibody was omitted, indicating nonspecific staining. The specific staining was abolished when the anti-PEPT1 serum was preabsorbed with the antigenic peptide (Fig. 5f ).
DISCUSSION
Various physiological aspects of intestinal peptide handling and transport have been characterized in recent years (1) . Enzymatic hydrolysis of dietary proteins to short-chain peptides by pancreatic and intestinal brush-border peptidases can cause the release of up to 400 different dipeptides and up to 8,000 different tripeptides. These peptides, which cover a range of molecular masses from 96.2 (diglycine) to 522.6 Da (tritryptophan), are all substrates of the intestinal high-capacity low-affinity peptide transporter PEPT1. The diversity of substrates recognized by PEPT1 is even greater taking into account the large number of peptidomimetics or the great variety of artificial substrates that we used (12) to elucidate the minimal molecular requirements for PEPT1-mediated transport.
The tissue distribution of PEPT1 in rat intestine has previously been determined by immunohistochemistry, and immunoreactivity was localized to absorptive enterocytes (30, 31) . In situ hybridization studies (16) performed in rabbit small intestine revealed PEPT1 mRNA in the cytoplasm of mature enterocytes. In the human small intestine, a previous study (49) revealed a distribution of PEPT1 immunoreactivity similar to the pattern in rat and rabbit tissues, and functional studies (41) reported PEPT1-specific kinetics. For the murine intestine, carnosine-uptake studies (35) with brush-border membrane vesicles demonstrated a PEPT1-mediated transport. However, studies uniting both morphological and functional aspects had not been performed until now. We combined ex vivo uptake studies with immunohistochemistry to colocalize immunoreactive PEPT1 protein with its transport function.
In the current study, we unequivocally demonstrated that 1) human and murine enterocytes express a functional uptake system for peptides in their luminal brush-border membranes that is shared by classical H ϩ / peptide transporter specific substrates; 2) the peptide transport system is located in different sections of the small intestine but not in the colon; and 3) the peptide transporter PEPT1 is localized to the same structures that display an uptake activity in situ.
The newly developed technique of intestinal ex vivo uptake studies allows the identification and visualization of the physiologically relevant translocation process of peptides and derivatives. This technique may be of special interest for further pharmacological studies in human tissue preparations. D-Ala-Lys-AMCA was chosen as a reporter substrate for the uptake studies because of its specificity for the peptide transporter (10, 32) . To prevent or reduce hydrolysis by brushborder membrane peptidases, an NH 2 -terminal D-Alaresidue was incorporated into the reporter to render it hydrolysis resistant. Uptake of fluorescent D-Ala-Lys-AMCA fragments by the transport systems for free amino acids was, in addition, prevented by the use of a specific medium (MEM 21011) containing various single amino acids that could compete with uptake of reporter fragments eventually produced by hydrolysis.
Different control studies were carried out to verify the specificity of reporter uptake by the transporter. It was shown that the transport of D-Ala-Lys-AMCA is competitively inhibited by higher concentrations of Gly-L-Gln, cefadroxil, and captopril. These compounds have been previously characterized as PEPT1 substrates and are of pharmacological interest because of their action as antibiotics (50) or ACE inhibitors (48) . Moreover, the transport was blocked by diethylpyrocarbonate, which is known to act as an inhibitor for PEPT1 (23, 44) . Passive diffusion of D-Ala-Lys-AMCA into the cells was ruled out by the lack of staining of the enterocytes surrounding the cells and the lack of tissue fluorescence in the cells when tissues were incubated at 4°C as demonstrated previously (18) .
The finding that transport activity and PEPT1 are present in all mature murine absorptive enterocytes parallels the importance of PEPT1 as a delivery system for dietary amino acids in the small intestine. Transport activity as well as PEPT1 immunoreactivity declined toward the base of the villi and the crypt compartment, providing functional evidence for a previously (30) suggested distributional pattern of the transporter. In this region of the human and murine intestinal mucosa, stem cells move up the villus axis and differentiate to mature enterocytes with absorptive function and to excretory goblet cells (7) . A similar distribution has been described for the two glucose transporters sodium-glucose cotransporter-1 (20, 43) and facilitated glucose transporter-2 (47), which were characterized as markers of the state of enterocyte cell differentiation. The expression of the PEPT1 protein and its transport activity therefore display a very similar developmental pattern.
Our previous findings that ␦-ALA is a substrate of PEPT1 (11) is of particular importance for human small intestinal epithelial cells. ␦-ALA is used in photodynamic therapy (PDT; 36) as a substrate for intracellular porphyrine synthesis (13) . The accumulation of porphyrins after administration of ␦-ALA promotes apoptosis and tissue necrosis on photoactivation, and therefore epithelial neoplasms can successfully be treated by PDT (33) . Because ␦-ALA is used in the treatment of a variety of cancers, including esophageal and small intestinal neoplasms, we provide data for the possible uptake mechanism and the sites for its uptake into absorptive epithelia.
In conclusion, we have demonstrated and visualized mammalian intestinal peptide transport ex vivo and identified the cellular sites of PEPT1 expression in the intestinal tract. Together with recent findings (46) on the dietary regulation of PEPT1 mRNA and protein expression and its minimal molecular requirements for substrate specificity (12), our results provide new insight into the intestinal uptake mechanism of dietary amino acids in peptide-based form as well as for peptide-based drugs and related xenobiotics. The D-AlaLys-AMCA uptake visualization assay might be a useful tool to characterize compounds that utilize PEPT1 for uptake into epithelial cells or that inhibit transport activity specifically.
